Immunomedics (IMMU) Presents Updated Results With IMMU-132 in Heavily-Pretreated Patients With Metastatic UC
Tweet Send to a Friend
Immunomedics, Inc., (NASDAQ: IMMU) today announced that sacituzumab govitecan (IMMU-132) is active in patients with metastatic urothelial cancer (UC) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
